The role of platelets in inflammation

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 449-458

  Thomas, Mark R ^a   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Immune response; Infection; Inflammation; Platelets; Thrombosis

Indexed keywords

CD40 LIGAND; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; RANTES; STROMAL CELL DERIVED FACTOR 1; THROMBIN; THROMBIN RECEPTOR; THROMBOCYTE FACTOR 4; THROMBOXANE A2; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID;

ADAPTIVE IMMUNITY; ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR INFLAMMATION; CELL INTERACTION; COMPLEMENT SYSTEM; HUMAN; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE FUNCTION; LYMPHOCYTE; MACROPHAGE MIGRATION; MALARIA; METASTASIS; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; UPREGULATION; ANIMAL; BLOOD; CELL COMMUNICATION; COMMUNICABLE DISEASE; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LEUKOCYTE; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; CELL COMMUNICATION; COMMUNICABLE DISEASES; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; NEOPLASMS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84940658117     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1067     Document Type: Article

References (128)

1. Semple JW, et al. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264–274
2. Varenhorst C, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60: 1623–1630
3. Varenhorst C, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart 2014; 100: 1762–1769
4. Storey RF, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014; 25: 517–525
5. Akinosoglou K, et al. Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res 2014; 133: 131–138
6. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339–3347
7. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963–974
8. Italiano JE, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost 2003; 1: 1174–1182
9. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996; 88: 1525–1541
10. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115: 3355–3362
11. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447–453
12. Storey RF, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925–934
13. Kulkarni S, et al. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783–791
14. Coppinger JA, et al. Moderation of the platelet releasate response by aspirin. Blood 2007; 109: 4786–4792
15. Duerschmied D, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008–1015
16. Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets 2001; 12: 261–273
17. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23: 177–189
18. Yeaman MR, et al. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 1998; 101: 178–187
19. Nesmelova IV, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005; 280: 4948–4958
20. Deuel TF, et al. Platelet Factor-4 Is Chemotactic for Neutrophils and Monocytes. Proc Natl Acad Sci USA 1981; 78: 4584–4587
21. Petersen FF, et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998; 161: 4347–4355
22. Scheuerer B, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158–1166
23. Kasper BB, et al. Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signalling pathways. J Immunol 2007; 179: 2584–2591
24. Hundelshausen von P, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924–930
25. Yu G, et al. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood 2005; 105: 3545–3551
26. Mause SF, et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512–1518
27. la Motte de C, et al. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011–2015
28. Lindemann S, et al. Activated platelets mediate inflammatory signalling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485–490
29. Pillitteri D, et al. Thrombin-induced interleukin 1beta synthesis in platelet suspensions: impact of contaminating leukocytes. Platelets 2007; 18: 119–127
30. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990; 85: 731–738
31. Loppnow H, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91: 134–141
32. Ignarro LJ, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; 98: 4202–4208
33. Bevilacqua MP, et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76: 2003–2011
34. Gawaz M, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75–85
35. Deshmane SL, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313–326
36. Blann A. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166–2179
37. Stenberg PEP, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880–886
38. Spertini OO, et al. P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor cells. J Cell Biol 1996; 135: 523–531
39. Symon FA, et al. Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol 1996; 157: 1711–1719
40. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998; 16: 111–135
41. Anand SX, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377–384
42. Lindmark E, et al. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol; 2000; 20: 2322–2328
43. Elzey BD, et al. Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood 2008; 111: 3684–3691
44. Henn V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–594
45. Déchanet J, et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997; 159: 5640–5647
46. Henn V. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047–1054
47. Lim HS. Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention. Circulation 2004; 109: 2524–2528
48. Aukrust P, et al. Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina : Possible Reflection of T Lymphocyte and Platelet Involvement in the Pathogenesis of Acute Coronary Syndromes. Circulation 1999; 100: 614–620
49. Garlichs CD, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649–655
50. Klesney-Tait J, et al. The TREM receptor family and signal integration. Nat Immunol 2006; 7: 1266–1273
51. Haselmayer P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029–1035
52. Evangelista V, et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: Role of PSGL-1 as a signalling molecule. Blood 1999; 93: 876–885
53. Mine S, et al. Activated platelets and endothelial cell interaction with neutrophils under flow conditions. Intern Med 2001; 40: 1085–1092
54. Doré MM, et al. P-selectin mediates spontaneous leukocyte rolling in vivo. Blood 1993; 82: 1308–1316
55. Buttrum SM, et al. Selectin-mediated rolling of neutrophils on immobilized platelets. Blood 1993; 82: 1165–1174
56. Yeo EL, et al. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood 1994; 83: 2498–2507
57. Moore KL, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol 1995; 128: 661–671
58. da Costa Martins PA, et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 2006; 79: 499–507
59. Ma Y-Q, et al. P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of alphaMbeta2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils. Blood 2004; 104: 2549–2556
60. Blanks JE, et al. Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta(2)-integrin mediated cell attachment to ICAM-1. Eur J Immunol 1998; 28: 433–443
61. Peters MJ, et al. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 1999; 106: 391–399
62. Weyrich AS, et al. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 1995; 95: 2297–2303
63. Tersteeg C, et al. FLow-induced PRotrusions (FLIPRs): a platelet-derived platform for the retrieval of microparticles by monocytes and neutrophils. Circ Res 2014; 114: 780–791
64. Passacquale G, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011; 6: e25595–5
65. Brown KA, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157–169
66. Salter JW, et al. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1432–1439
67. Singbartl K, et al. Platelet, but not endothelial, P-selectin is critical for neutrophil- mediated acute postischemic renal failure. FASEB J 2001; 15: 2337–2344
68. Asaduzzaman M, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37: 1389–1396
69. Zarbock A, et al. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116: 3211–3219
70. Sarma J, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–2171
71. Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015; 114: 490-497
72. Thomas MR, et al. A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets 2014; 25: 612–618
73. Hohlfeld T, Schrör K. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions? Thromb Haemost 2015; 114: 469-477
74. Capra V, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014; 12: 126–137
75. Larsen SB, et al. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost 2015; 114: 519-529
76. Schrottmaier WC, et al. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost 2015; 114: 478-489
77. Brühl von M-L, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819–835
78. Rock KL, et al. The Sterile Inflammatory Response. Ann Rev Immunol 2010; 28: 321–342
79. Zheng Y, et al. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2011; 31: 2781–2786
80. Cognasse F, et al. The inflammatory role of platelets via their TLRs and Siglec receptors. Front Immunol 2015; Epub ahead of print.
81. Orlova VV, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26: 1129–1139
82. Maugeri N, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost 2014; 12: 2074–2088
83. Hilf N, et al. Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 2002; 99: 3676–3682
84. Cox D, et al. Platelets and the innate immune system: mechanisms of bacterialinduced platelet activation. J Thromb Haemost 2011; 9: 1097–1107
85. Shannon O, et al. Severe streptococcal infection is associated with M protein-induced platelet activation and thrombus formation. Mol Microbiol 2007; 65: 1147–1157
86. Brennan MP, et al. Elucidating the role of Staphylococcus epidermidis serine-aspartate repeat protein G in platelet activation. J Thromb Haemost 2009; 7: 1364–1372
87. O’Seaghdha M, et al. Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J 2006; 273: 4831–4841
88. Plummer C, et al. A serine-rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb. Br J Haematol 2005; 129: 101–109
89. McNicol A, et al. Streptococcus sanguinis-induced cytokine release from platelets. J Thromb Haemost 2011; 9: 2038–2049
90. Herzberg MC, Krishnan LK. Involvement of a2-Adrenoreceptors and G Proteins in the Modulation of Platelet Secretion in Response to Streptococcus sanguis. Crit Rev Oral Biol Med 1993; 4: 435–442
91. Baughman RP. Thrombocytopenia in the intensive care unit. Chest 1993; 104: 1243
92. Russwurm S, et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17: 263–268
93. Aslam R, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide- induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637–641
94. Koupenova M, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. Blood 2014; 124: 791–802
95. Lu Y-C, et al. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145–151
96. Ward JR, et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 2005; 94: 831–838
97. Andonegui G. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417–2423
98. Clark SR, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463–469
99. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 2012; 198: 773–783
100. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012; 189: 2689–2695
101. Caudrillier A, et al. Platelets induce neutrophil extracellular traps in transfusion- related acute lung injury. J Clin Invest 2012; 122: 2661–2671
102. McDonald B, et al. Intravascular Neutrophil Extracellular Traps Capture Bacteria from the Bloodstream during Sepsis. Cell Host Microbe 2012; 12: 324–333
103. Rossaint J, et al. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. Blood 2014; 123: 2573–2584
104. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768–2776
105. Mangold A, et al. Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size. Circ Res 2015; 116: 1182–1192
106. Totani L, et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost 2012; 107: 1130–1140
107. Hagiwara S, et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011; 35: 289–292
108. Lipcsey M, et al. Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets 2005; 16: 408–414
109. Ricklin D, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785–797
110. Peerschke EI, et al. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170–2175
111. Patzelt J, et al. Platelets and the complement cascade in atherosclerosis. Front Physiol 2015; 6: 49
112. Del Conde I, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med; 2005; 201: 871–879
113. Hamad OA, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6: 1413–1421
114. Yin W, et al. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19: 225–233
115. Morrell CN, et al. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; 123: 2759–2767
116. McMorran BJ, et al. Platelets Kill Intraerythrocytic Malarial Parasites and Mediate Survival to Infection. Science 2009; 323: 797–800
117. McMorran BJ, et al. Platelet Factor 4 and Duffy Antigen Required for Platelet Killing of Plasmodium falciparum. Science 2012; 338: 1348–1351
118. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012; 2012: 676731–676736
119. Schlesinger M, et al. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Thromb Res 2014; 133: 855–862
120. Rothwell PM, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591–1601
121. Schrör K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 2011; 25: 473–484
122. Maurer MM, Stebut von EE. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36: 5–5
123. Lindmark E, et al. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322–2328
124. Cox D, et al. Platelets and the innate immune system: mechanisms of bacterialinduced platelet activation. J Thromb Haemost 2011; 9: 1097–1107
125. Bouchon AA, et al. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164: 4991–4995
126. Brown GT, McIntyre TM. Lipopolysaccharide signalling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1b-rich microparticles. J Immunol 2011; 186: 5489–5496
127. Italiano JE, et al. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010; 17: 578–584
128. Vajen T, et al. Microvesicles from platelets: novel drivers of vascular inflammation. Thromb Haemost 2015; 114: 228–236.